论文部分内容阅读
目的 分析不同SARS抗病毒治疗方法的效果 ,为制定SARS抗病毒治疗方案提供参考。方法 采用临床流行病学回顾研究 ,使用SPSS11.0软件分析我院SARS患者的住院病历 ,分析选择不同抗病毒治疗药物治疗SARS的T细胞亚群、血象、肝肾功能变化及临床效果。结果 本文研究发现 ,利巴韦林治疗病死率为 18.0 3% ;干扰素组T细胞亚群下降值最低 ,但治愈率为 10 0 % ,与利巴韦林组比较 (P <0 .0 0 1)统计学有极显著性差异 ,并有延长T细胞亚群下降至最低值时间的趋势 (P >0 .0 5 ) ;干扰素与利巴韦林联合治疗可延长T细胞亚群下降至最低值的时间 ,CD3 与利巴韦林组比较 (P <0 .0 5 )统计学有显著性差异 ,病死率为 6 .0 6 % ,与利巴韦林组比较 (P <0 .0 5 )统计学有显著性差异 ,并低于文献报道水平 (6 .5 % )。干扰素组对SARS患者血象及肝肾功能的影响最小 ,各组与利巴韦林组比较 (P >0 .0 5 )统计学无显著性差异。结论 干扰素或干扰素联合利巴韦林抗病毒治疗效果优于单独使用利巴韦林的效果。干扰素抗病毒治疗效果最好。
Objective To analyze the effect of antiviral treatment of different SARS and to provide a reference for developing antiviral treatment of SARS. Methods A retrospective clinical epidemiological study was conducted. SPSS11.0 software was used to analyze the inpatient records of patients with SARS in our hospital. The changes of T cell subsets, blood, hepatic and renal functions and clinical effects of different antiviral drugs in treating SARS were analyzed. Results The study found that the ribavirin treatment mortality was 18.0 3%; interferon group T-cell subsets decreased the lowest, but the cure rate was 10 0%, compared with ribavirin group (P <0 0 0 1) There was a statistically significant difference, and there was a trend of prolonging the time when the T cell subsets decreased to the lowest value (P> 0.05); the combination of interferon and ribavirin could prolong the T cell subsets down to In the lowest time, statistically significant difference was found between CD3 and ribavirin group (P <0.05), the case fatality rate was 6.06%, compared with ribavirin group (P <0. 0 5) There was a statistically significant difference, and lower than the reported level (6.5%). Interferon group has the least effect on blood and liver and kidney function in patients with SARS. There was no significant difference between each group and ribavirin group (P> 0.05). Conclusion Interferon or interferon combined with ribavirin is better than ribavirin alone. Interferon anti-viral treatment best.